Toronto, Canada
Phenomic is a Canadian biotech startup with a mission to enhance survival rates for patients with difficult-to-treat solid tumors, including colorectal, pancreatic, and breast cancers. Established in 2017, the company operates at the intersection of AI, biotechnology, and machine learning within the health and wellness sector. Phenomic aims to revolutionize cancer treatment by addressing historical challenges in drug discovery, attributable to inadequate tumor models.
Its innovative ML-powered transcriptomics platform offers a cutting-edge solution by analyzing the interactions of diverse cell types in human tumors, thereby pinpointing effective targets. The company's flagship program involves a unique CD3 engager, which promises to mitigate the limitations of traditional tumor-associated antigens, showcasing promising results in trials and now progressing as a development candidate.
Backed by a robust investor base, Phenomic secured a $6.00M Seed Round on 07 October 2020, involving AV8 Ventures, Viva BioInnovator, CTI Life Sciences Fund, Garage Capital, Hike Ventures, Toronto Innovation Acceleration Partners, and Cantos. This startup is uniquely poised to deliver groundbreaking therapeutics through its advanced platform, potentially capturing investor interest in the rapidly evolving landscape of cancer treatment.
